All regulatory updates
718 results found
MOFCOM and GACC Announcement No. 18 of 2025 adds export licensing controls for specified medium/heavy rare earth-related items (control numbers 1C902–1C908)
MOFCOM and the General Administration of Customs issued Announcement No. 18 of 2025 imposing export controls (license requirement and customs declaration requirements) on certain medium and heavy rare earth-related items, including samarium-, gadolinium-, terbium-, dysprosium-, lutetium-, scandium-, yttrium-, and related permanent-magnet materials/oxides/compounds, aligned to listed dual-use control numbers (1C902–1C908). The announcement highlights practical compliance duties: exporters must apply for export licenses under PRC export control authorities, identify controlled items in customs declarations (including the dual-use item control number), and be prepared for customs questioning/withholding of release. (Note: this event is already present in the existing announcements list; included here would normally be a duplicate and should be skipped in downstream ingestion.)
MOFCOM & GACC Announcement No.18 of 2025 imposes export licensing controls on specified medium/heavy rare earth-related items
China’s MOFCOM and GACC issued Announcement No.18 of 2025 establishing export controls (export licensing requirements) for specified medium/heavy rare earth-related items, including certain forms of samarium, gadolinium, terbium, dysprosium, lutetium, scandium, and yttrium (e.g., metals, alloys, targets, oxides, and compounds/mixtures, including certain permanent magnet material-related categories). The measure requires exporters to apply for export licenses and to correctly identify controlled items in customs declarations (including the applicable dual-use item control number), with customs empowered to hold shipments if declarations are questioned. The announcement states it takes effect on the date of issuance.
European Commission publishes Omnibus package communication outlining proposed CSRD simplifications
The European Commission published an ‘Omnibus package’ update describing a simplification initiative that includes proposed changes impacting CSRD (e.g., potential scope recalibration and ESRS simplification). This is an official policy/proposal communication (not the final legal text). Compliance teams should treat this as proposal-stage and monitor the legislative process and subsequent Official Journal publication for any adopted amendments.
Illinois SB1773 amendment filed (sam003) detailing xylazine exemptions for veterinary/animal-drug and certain professional uses
An Illinois SB1773 committee amendment (sam003), filed 2025-04-01, provides detailed statutory exemption language (new Section 309.1) stating that, notwithstanding the Schedule/Class III scheduling of xylazine, xylazine is not considered a controlled substance when used/handled under specified conditions (including certain licensed veterinarian use for nonhuman species involving FDA-approved animal drugs, use as an API for manufacturing an FDA-approved animal drug, use by licensed certified euthanasia technicians employed by certified euthanasia agencies, and wildlife biologist fieldwork under indirect veterinarian supervision). Compliance teams should use the amendment text to assess whether current/anticipated xylazine activities would fall under exemptions if SB1773 is enacted.
Nevada Attorney General Opinion 2025-01 interprets NRS 453 controlled-substance authority for homeopathic physicians
Nevada Attorney General Opinion No. 2025-01 provides an official legal interpretation regarding how Nevada controlled substances law (including NRS 453) applies to singly licensed homeopathic physicians. The opinion discusses conditions/limitations for possession, administration, prescribing, and dispensing of controlled substances, including registration expectations (Nevada Board of Pharmacy controlled substances registration and DEA registration) and the limited scope tied to accepted homeopathic practice. Compliance impact: healthcare providers and compliance teams supporting homeopathic practice in Nevada should review the opinion for constraints and registration/oversight expectations when controlled substances are involved.
Nevada Attorney General Opinion No. 2025-01 discusses controlled-substance prescribing/possession authority and registration issues under NRS 453
Nevada Attorney General Opinion No. 2025-01 provides an official legal interpretation addressing issues involving controlled substances under NRS 453 (Nevada Uniform Controlled Substances Act), including discussion of authorization/registration considerations relevant to prescribing/possession in the context analyzed by the opinion. While not a codified amendment, the opinion can materially affect compliance expectations for regulated practitioners and entities by clarifying legal interpretation applied in Nevada.
Nevada Attorney General Opinion No. 2025-01 interprets controlled-substance authority under NRS 453 for homeopathic physicians
Nevada Attorney General Opinion No. 2025-01 provides an official legal interpretation concerning the application of NRS 453 (Nevada Uniform Controlled Substances Act) to homeopathic physicians. The opinion discusses whether, and under what limitations, singly licensed homeopathic physicians may possess/administer/prescribe/dispense controlled substances, and emphasizes requirements tied to Board of Pharmacy controlled substances registration and DEA registration. Compliance impact: healthcare providers and compliance teams should review the opinion when evaluating practitioner authority and registration obligations under NRS 453 for controlled substances activities.
Illinois HB0077 proposed to add xylazine to Schedule III and create exemptions for veterinary and related lawful uses (last action Mar 21, 2025)
HB0077 (104th General Assembly) proposes amending the Illinois Controlled Substances Act to schedule xylazine as a Schedule III controlled substance and to establish explicit exemptions for defined lawful activities (e.g., use by licensed veterinarians in professional practice; certain euthanasia technicians; wildlife biologists under veterinary supervision; other specified lawful uses). The bill status page shows last action on 2025-03-21 (re-referred to Rules Committee). If enacted, regulated entities (veterinary practices, suppliers, facilities handling xylazine) would need to implement controlled-substance handling controls unless covered by an exemption.
OEHHA adds vinyl acetate to the Proposition 65 list as a chemical known to cause cancer (warnings enforceable starting Jan 3, 2026)
OEHHA listed vinyl acetate under Proposition 65 as a chemical known to cause cancer (listing effective January 3, 2025). The Prop 65 warning requirement for significant exposures becomes enforceable starting January 3, 2026 (one-year grace period typical for new listings). Compliance teams should assess products/operations that may expose California consumers/workers to vinyl acetate and implement compliant Prop 65 warnings and related substantiation/documentation before the enforceability date.
European Commission updates EU List of Waste with new battery-related waste codes (including hazardous classification for “black mass”)
The European Commission announced an update to the EU List of Waste introducing new battery-related waste codes spanning manufacturing waste, post-consumer battery waste, and intermediate recycling fractions. The update clarifies/classifies “black mass” as hazardous waste and classifies several battery chemistries (including lithium-, nickel-, zinc-based; sodium sulphur; alkaline waste batteries) as hazardous, including adding a new hazardous code for lithium-based batteries in separately collected municipal waste. This affects waste classification, handling, storage, and cross-border shipment compliance (e.g., documentation and shipment controls) for battery producers, collectors, recyclers, and logistics providers supporting EU Battery Regulation circularity requirements.
Commission Regulation (EU) 2025/351 amends EU plastics FCM rules, recycled plastics framework and GMP requirements; repeals Regulation (EC) No 282/2008
Commission Regulation (EU) 2025/351 (published in the Official Journal on 24 Feb 2025) amends several key implementing measures under the EU Food Contact Materials framework (Regulation (EC) No 1935/2004). It updates Regulation (EU) No 10/2011 (plastics) with clarifications on scope and compositional requirements (including delineation of non-plastic layers such as inks/coatings/adhesives), strengthens/clarifies expectations around the purity of substances used in plastic FCMs (including considerations for substances produced from waste and alignment for UVCB-type substances), and introduces/clarifies information requirements for repeated-use plastic articles (user instructions to mitigate deterioration that could increase migration). It also amends the recycled plastics regime (Regulation (EU) 2022/1616), repeals Regulation (EC) No 282/2008, and amends GMP rules (Regulation (EC) No 2023/2006). Compliance teams should reassess plastics and recycled-plastics compliance dossiers (purity/specifications, supporting documentation/DoC content, repeated-use instructions/labeling where applicable) and confirm supply chain readiness for the amended requirements.
Commission Regulation (EU) 2025/351 amends Plastics FCM rules (Reg. (EU) 10/2011) and related FCM measures (recycled plastics/GMP)
Commission Regulation (EU) 2025/351 amends the EU Plastics Food Contact Materials Regulation (EU) No 10/2011 (a specific measure under the Framework Regulation (EC) No 1935/2004) and also makes connected amendments across the EU FCM compliance regime (including recycled plastics and GMP-related provisions, per the research summary). Compliance teams should review impacts on plastics FCM substance control/quality expectations and related documentation/labelling and operational controls referenced in the amending act.
CARB Executive Order W-25-019 approves Lukasiewicz Research Network – Poznan Institute of Technology – Wood Technology Center as a CARB Third-Party Certifier (TPC-19) and supersedes EO W-22-019
CARB issued Executive Order (EO) W-25-019 approving (re-approving) Lukasiewicz Research Network – Poznan Institute of Technology – Wood Technology Center as a CARB-approved Third-Party Certifier (TPC-19) under 17 CCR §93120.4 for hardwood plywood, particleboard, and medium density fiberboard, superseding EO W-22-019. This administrative approval affects which certification bodies composite wood manufacturers may use to meet ATCM third-party certification obligations for California sales.
CARB Executive Order W-25-019 re-approves Lukasiewicz Research Network – Poznan Institute of Technology – Wood Technology Center as a Third-Party Certifier (TPC-19) under 17 CCR §93120.4
CARB issued Executive Order W-25-019 re-approving Lukasiewicz Research Network – Poznan Institute of Technology – Wood Technology Center as a CARB Third-Party Certifier (TPC-19) under 17 CCR §93120.4 for certification activities supporting compliance with the Composite Wood Products Formaldehyde ATCM (17 CCR §§93120–93120.12). The EO supersedes the prior EO W-22-019 and reiterates operational conditions relevant to regulated entities (e.g., subcontractor controls, participation in inter-laboratory studies, notification obligations, recordkeeping, and annual reporting due on/before March 1 each year). This matters for manufacturers because ATCM compliance pathways rely on using CARB-approved TPCs for certification/verification.
Illinois Public Act 103-1064 amends Illinois Controlled Substances Act on chronic pain prescribing and Prescription Monitoring Program (PMP) confidentiality/access
Public Act 103-1064 (HB 5373) amends the Illinois Controlled Substances Act, including provisions affecting opioid/chronic pain prescribing and the Illinois Prescription Monitoring Program (ILPMP). The amendment states that ordering/prescribing/dispensing/administering/paying for controlled substances (including opioids) must not be predetermined by specific morphine milligram equivalent (MME) guidelines except as provided under federal law. It also tightens/clarifies conditions for release of confidential PMP data, requiring a written showing of a valid court order/subpoena or an administrative subpoena issued by IDFPR, and excludes 42 CFR Part 2–protected records/opioid treatment program confidential information from inter-agency sharing. Compliance teams should review controlled-substance prescribing policies, PMP access/request procedures, and data handling workflows to ensure subpoena/court-order gating and Part 2 segregation are implemented.
Illinois HB2804 proposed fentanyl-specific offenses/penalties including Class X felony for selling/dispensing fentanyl-containing drugs and enhancements for certain fentanyl presentations (referred to House Rules Feb 6, 2025)
HB2804 (104th General Assembly) proposes amendments to the Illinois Controlled Substances Act (including Sections 401 and 401.1 per the bill materials) to create/expand fentanyl-specific criminal provisions. The introduced bill materials describe Class X felony treatment for knowingly/unlawfully selling or dispensing any scheduled drug containing a detectable amount of fentanyl, an additional felony for using an electronic communication device in furtherance of trafficking involving fentanyl, and additional sentencing provisions for specified fentanyl/carfentanil amounts and presentations. The ILGA status page shows last action 2025-02-06 (referred to House Rules Committee).
HB2804 introduced to create/expand Class X fentanyl provisions and add packaging-based and device-use enhancements
Illinois HB2804 (104th GA) proposes amendments to the Illinois Controlled Substances Act to establish or expand Class X felony treatment for certain fentanyl-involved selling/dispensing conduct, add a separate Class 1 felony provision tied to using an electronic communication device in furtherance of fentanyl-related trafficking, and add additional sentencing enhancement concepts based on form/packaging (e.g., product forms resembling consumer candy/branding). Compliance relevance: if enacted, it would increase criminal exposure associated with fentanyl-containing substances and introduce new enhancement triggers that could affect enforcement and compliance risk assessments.
Illinois HB2931 introduced to amend the Illinois Controlled Substances Act (bill text available)
Illinois HB2931 was introduced (104th General Assembly) and includes amendments affecting the Illinois Controlled Substances Act (720 ILCS 570). Compliance teams should monitor the bill’s progress because, if enacted, it would change statutory obligations/authorities under the ICSA (specific operational impacts depend on the final enacted language and any implementing agency guidance).
Illinois HB2804 referred to House Rules Committee; bill proposes Class X felony and additional enhancements for fentanyl/carfentanil-related conduct
Illinois HB2804 (104th General Assembly) proposes amendments to the Illinois Controlled Substances Act to create and expand fentanyl/carfentanil-specific offenses and sentencing enhancements. The proposal includes making selling/dispensing any scheduled drug containing a detectable amount of fentanyl a Class X felony (with specified sentencing and fine ranges), creating additional penalties for use of electronic communication devices in fentanyl-related trafficking, and adding an additional 5-year sentence when fentanyl is presented in consumer-appealing forms (e.g., candy/gummy-like or similar trade dress). The official bill status shows it was referred to the House Rules Committee on 2025-02-06. Compliance teams should monitor due to potential substantial increases in criminal liability exposure if enacted.
Illinois SB1773 introduced to schedule xylazine as Class III controlled substance; bill text states effective Jan 1, 2026 (proposal)
SB1773 (104th General Assembly) proposes amendments to the Illinois Controlled Substances Act to schedule xylazine as a Class III controlled substance; the bill PDF synopsis states an effective date of 2026-01-01. An amendment document was also identified that adds xylazine exemption language (e.g., circumstances where xylazine would not be considered a controlled substance). Stakeholders should monitor because scheduling would create new controlled-substance compliance obligations for entities handling xylazine unless exempted.